Brooks Laboratories share price
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Brooks Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹60.56down ₹3.28 (5.14%)BSE ₹60.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹63.84.
30 Oct: open ₹65.80, high ₹66.00, low ₹59.70
52-week range of traded prices to 30 Oct 2026
₹36.30Low, 30 Mar 2026₹116.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹178 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.45
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,79557.7% delivered
Results
Standalone, as consolidated accounts are on record for only 6 of the last ten years; ₹ crore.Brooks Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −7.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +550.4%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹23 Crup 13.61%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.42 Crup 130.93%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.2%
Revenue by quarter
Peak revenue ₹26 Cr, quarter to Jun 2025; lowest ₹17 Cr, quarter to Dec 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8 | 20.5 | 23.3 | 25.5 | 23.5 | 16.6 | 20.2 | 23.0 |
| Net profit | 1.0 | 0.9 | 1.4 | 2.7 | 2.2 | 0.3 | 0.6 | 1.4 |
| Net margin | 4.6% | 4.6% | 5.9% | 10.4% | 9.5% | 1.8% | 3.0% | 6.2% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹86 Crup 3.85%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5.81 Crup 90.19%
- Net margin
- 6.8%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2022, the company's revenue for that year, ₹77 Cr, differs from its quarters added, ₹76 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.5 | 56.9what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹1.19 crore, a tax on the goods the company makes that it collects and pays to the government. | 55.0 | 69.7 | 77.2 | 77.0 | 55.5 | 79.5 | 82.6 | 85.7 |
| Net profit | 2.0 | −13.8 | −14.8 | −24.4 | −15.6 | 0.7 | −8.2 | 1.5 | 3.1 | 5.8 |
| Net margin | 3.4% | −24.3% | −26.9% | −35.0% | −20.2% | 0.9% | −14.7% | 1.9% | 3.7% | 6.8% |
Standalone. Years to March. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- ManufacturingManufacturing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹82.9 Cr96.7%
- TradingTrading, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹2.9 Cr3.3%
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2022: days before it are of the company before the change.Brooks Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 63% of 247 trading days over the last year.
LowestHighest
Its median10.45Industry median27.77
Price to book
At or below today's level on 5% of 1,089 trading days over the last 5 years.
LowestHighest
Its median3.33Industry median2.89
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −65.1% | +90.2% | −81.7% | 0.0% |
| 3 years | −15.9% | – | – | 0.0% |
| 5 years | −9.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 quant Business Cycle Fundquant Mutual Fund | 29,16,111 | 1.75% | ₹16.3 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Brooks Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Brooks Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Gennex LaboratoriesGENNEX | 195 | 10.60 | 0.88 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
 Kerala AyurvedaKERALAYUR | 192 | – | – | +10.4% | – | −257.3% | −24.1% | 0.00% |
| Bio Medica LaboratoriesBMLL | 189 | 16.16 | – | – | – | 44.2% | – | 0.00% |
 Syschem (India)SYSCHEM | 180 | – | 1.29 | +40.3% | – | – | 10.4% | 0.00% |
 Oxygenta PharmaceuticalOXYGENTAPH | 175 | – | – | +20.6% | – | – | −15.1% | 0.00% |
 Coral LaboratoriesCORALAB | 173 | 9.01 | 0.83 | −5.4% | +7.2% | 9.4% | 7.6% | 0.41% |
 Asston PharmaceuticalsAPL | 165 | 318.43 | – | – | – | 1.3% | −2.0% | 0.00% |
 Gujarat Inject (Kerala)GUJINJEC | 163 | 54.64 | 13.82 | +151.6% | +209.0% | 27.4% | 32.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Brooks Laboratories announcements
Oct 2026
14 Oct · Board meeting
13 Oct
12 Oct · Legal
Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Sep 2026
16 Sep · Management
Brooks Laboratories share price by year
Each calendar year to 2025.Brooks Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 80.14 | −55.5% | 194.97 | 70.49 |
| 2024 | 180.14 | +25.4% | 180.14 | 73.80 |
| 2023 | 143.60 | +31.4% | 162.50 | 57.90 |
| 2022 | 109.30 | +8.9% | 143.45 | 72.90 |
| 2021 | 100.35 | +51.0% | 150.30 | 52.40 |
| 2020 | 66.45 | +129.1% | 71.75 | 14.40 |
| 2019 | 29.00 | −52.2% | 60.55 | 23.45 |
| 2018 | 60.70 | −46.1% | 116.00 | 51.65 |
| 2017 | 112.65 | −15.0% | 156.45 | 101.85 |
| 2016 | 132.50 | +43.2% | 186.55 | 71.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 61.38 | 64.99 | 60.32 | 63.84 | 63.50 | 1,35,117 | 41.2% |
| 28 Oct 2026 | 59.55 | 61.42 | 58.93 | 59.90 | 60.05 | 23,697 | 48.3% |
| 27 Oct 2026 | 57.02 | 60.30 | 57.02 | 59.72 | 59.53 | 24,757 | 58.2% |
| 26 Oct 2026 | 59.90 | 60.94 | 55.50 | 57.86 | 58.84 | 53,859 | 52.4% |
| 23 Oct 2026 | 61.25 | 62.89 | 56.70 | 57.86 | 57.84 | 99,200 | 64.6% |
| 22 Oct 2026 | 60.20 | 64.29 | 59.10 | 61.09 | 62.22 | 54,438 | 48.4% |
| 21 Oct 2026 | 65.07 | 65.27 | 60.00 | 60.78 | 62.48 | 74,347 | 58.1% |
| 19 Oct 2026 | 66.75 | 69.40 | 64.50 | 65.07 | 66.51 | 47,904 | 57.4% |
| 16 Oct 2026 | 70.06 | 72.50 | 66.55 | 67.57 | 69.03 | 1,22,176 | 55.2% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 28 Jul 2023 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 11 Feb 2020 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- BROOKS
- BSE code
- 533543
- ISIN
- INE650L01011
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.brookslabs.net
- CIN
- L24232HP2002PLC000267
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2002
- Registered office
- Village Kishanpura, Nalagarh Road, Baddi, Solan 174101, Himachal Pradesh
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments